Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Heart failure in patients treated with bisphosphonates

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Biofilm formation - what we can learn from recent developments

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The challenges and possibilities of public access defibrillation

    Research output: Contribution to journalReviewResearchpeer-review

  4. Asthma, other atopic conditions and risk of infections in 105,519 general population never and ever smokers

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of fracture in adults on renal replacement therapy: a Danish national cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates. DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group. The risk of heart failure was estimated by Cox proportional hazard analyses. RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P 
Original languageEnglish
JournalJournal of Internal Medicine
Volume274
Issue number4
Pages (from-to)342-50
Number of pages9
ISSN0954-6820
DOIs
Publication statusPublished - Oct 2013

ID: 38706644